Lead US Patent Litigation Counsel, Life Sciences
Enregistrez cette offre et organisez votre recherche
Créez un compte gratuit pour enregistrer des offres d'emploi, créer des alertes et revenir à cette liste depuis votre tableau de bord.
En continuant, vous acceptez nos Conditions d’utilisation & Politique de confidentialité.
argenx is seeking an experienced US patent attorney to lead patent strategy and litigation readiness, focusing on BPCIA and ANDA disputes across global portfolios. You will partner with LCIP and external counsel to align dispute strategy with product development and portfolio value.
This role emphasizes collaboration with scientists and business teams, driving invention protection and cross-jurisdictional enforcement while integrating evolving agentic workflows and AI-enabled processes.
-
Senior US Patent Counsel
Il y a 4 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique Argenx Télétravail Temps plein 225 000 € - 310 000 € Contratargenx seeks a US‑patent attorney to build and execute global IP strategies, advise cross‑functional teams, and support transactions for a portfolio led by VYVGART and other assets. You will help shape an evolving agentic IP team where AI-assisted workflows operate under human review, enabling efficient protection and value creation.The role requires...
-
US Patent Attorney – Sr. Patent Counsel, Program Strategy
Il y a 4 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique argenx Temps plein 225 000 € - 310 000 € ContratJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...
-
US Patent Attorney, Sr. Patent Counsel, Program Strategy
Il y a 4 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique argenx Télétravail Temps plein 225 000 € - 310 000 € ContratJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...